Using SARS-CoV-2 red cell kodecytes to assess vaccine-induced immune response to the conserved 1147-58 region of the spike protein in Indian blood donors: exploring the potential role of blood transfusion services in population surveillance - 23/08/25
, Aniruddha Hazra a, Najla Haneefa Basheela a, Kaushik Gupta a, Pradip Kumar Mondal a, Elena Aliper b, Nicolai V. Bovin c, Stephen M. Henry d, ⁎
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Graphical abstract |
Highlights |
• | SARS-CoV-2 red cell kodecytes assay can detect vaccine-induced IgG antibodies using column agglutination technique. |
• | About 12% of vaccinated individuals do not have detectable antibodies to the conserved 1147-58 region of the SARS-CoV-2 spike protein. |
• | Blood transfusion services can play an important role in population surveillance. |
Abstract |
Background and objectives |
Blood transfusion services are uniquely poised to take part in the population surveillance study by providing snapshots of the SARS-CoV-2 immunity status among vaccinated blood donors. The immunogenic 1147-58 region of the intact SARS-CoV-2 spike protein is partly spatially hidden. These 1147-58-region-specific antibodies have previously been observed in COVID-19 infected patients but have not been documented in vaccinated individuals. In this study, we aimed to determine the immune response to this conserved region of the spike protein using SARS-CoV-2 red cell kodecytes among vaccinated blood donors.
Material and methods |
Three hundred fifteen voluntary blood donors of Indian ethnicity vaccinated twice against SARS-CoV-2 who, to their knowledge, had not had COVID-19 infection, were screened using quantitative chemiluminescent (CLIA) SARS-CoV-2 immunoassay (detecting total S1 IgG antibodies by measuring the binding antibody units [BAU]), as well as a SARS-CoV-2 red cell kodecytes assay detecting IgG antibodies specific to the 1147-58 region by column agglutination technique.
Results |
The CLIA assay was antibody-reactive with 100% of the 315 samples from vaccinated individuals (BAU/mL > 20), of which 311 (98.7%) were considered immune (BAU/mL > 58). Of the 315 CLIA-reactive samples, moderate to strong kodecyte serologic grades were observed for 63.2% (n = 199) of the samples, while 24.8% (n = 78) yielded weak serologic responses, and 12.1% (n = 38) were unreactive against kodecytes.
Conclusions |
These results show that about 12% of vaccinated individuals do not have detectable antibodies to the conserved 1147-58 region of the SARS-CoV-2 spike protein and suggest that future studies should clarify whether this has biological implications regarding long-term immune protection.
Le texte complet de cet article est disponible en PDF.Keywords : SARS-CoV-2, Vaccination, Antibody, Peptide epitope, Kodecyte, Function-spacer-lipid
Plan
Vol 32 - N° 3
P. 286-291 - août 2025 Retour au numéro
Article précédent
- Five-year review of acute transfusion reactions and transfusion errors at a tertiary center
- Tugcan Alp Kirkizlar
- Transfusion strategy and allo-immunization to red blood cell antigens after allogeneic hematopoietic stem cell transplantation with partial donor/recipient Rh matching
- Jeromine Beaufort, Alienor Xhaard, Aline Floch, Marie Robin, Flore Sicre de Fontbrune, David Michonneau, Florian Chevillon, Nathalie Dhedin, Matthieu Jestin, Eleonore Kaphan, Pedro Henrique de Lima Prata, Mathilde Ruggiu, Richard Traineau, Candice Cavalie, Gerard Socie, Regis Peffault de Latour, Anne-Claire Lepretre
Bienvenue sur EM-consulte, la référence des professionnels de santé.